title: [Which intravesical chemotherapy for what tumor of the bladder?].
abstract: The rationale for adjuvant chemoprophylaxis in superficial bladder cancer treated by transurethral resection is discussed. Many questions remain unsolved as far as chemoprophylaxis in concerned. The authors try to answer them through an analysis of the results of prospective and randomized studies undertaken by the EORTC genito-urinary group for 12 years. Advantages and disadvantages of the most common agents (Adriamycin, Epodyl, Mitomycin, Thiotepa, BCG) are analyzed; an attempt is done to define instillations regimens; indications and results of these adjuvant treatments are studied.
authors.affiliation: Service d'Urologie, Université de Liège, Belgique.
authors.forename: C
authors.initials: C
authors.lastname: Bouffioux
authors.forename: L
authors.initials: L
authors.lastname: Denis
authors.forename: K H
authors.initials: KH
authors.lastname: Kurth
authors.forename: M
authors.initials: M
authors.lastname: De Pauw
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000283:Administration, Intravesical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
vernacular_title: Quelle chimiothérapie intravésicale pour quelle tumeur de vessie?